ArticleNature biomedical engineering2021
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Open access · greenAbstract read
In one paragraph
Article in Nature biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 168 citations in OpenAlex.
- Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).Oncology letters · 2026Review
- Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2026Article
- Genetically inducible coordinators of cytokine signaling pathways for interrogating T cell motility.bioRxiv : the preprint server for biology · 2026Article
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.Cell · 2026Article
- Article
- Chemokine-Armed Oncolytic Viruses: Engineering Immune Cell Trafficking to Transform the Tumor Microenvironment.Pharmaceutics · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- GPCRs in CAR-T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Glycolysis-driven cancer-associated fibroblasts shape T-Cell exclusion via the CXCL16-CXCR6 Axis: a metabolic-chemokine mechanism in tumor immunity.Journal of translational medicine · 2026Review
- Organ-Specific Migration License (OSML) theory: a novel paradigm for spatiotemporal regulation and intervention of cross-organ immune cell migration in tumor immune responses.Cell communication and signaling : CCS · 2026Review
- Ablation of prostaglandin ENature biomedical engineering · 2026Article
- Integrated analysis identifies a CXCR6/CD45/PD-1-based risk model for melanoma prognosis and intratumoral CD8+/CD69 + T-cell infiltration correlation.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- C-X-C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8International journal of cancer · 2026Article
- Dual-targeting CD133/PD-L1 CAR-T plus αPD-1 overcomes immunosuppressive microenvironment and enhanced by radiation pre-conditioning.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy.Immuno-oncology technology · 2026Review
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors.Nature communications · 2026Article
- T cells assemble lentivirus to solve local delivery of stable gene therapy.Scientific reports · 2026Article
- CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives.iScience · 2026Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
58 authors at 11 institutions in 4 countries.
Stefanie Lesch *Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-2658-7666
Viktoria Blumenberg *Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-1379-0876
Stefan StoiberCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Adrian GottschlichCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-2898-4182
Justyna OgonekCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Bruno L CadilhaCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0001-7045-3898
Zahra DantesKlinik und Poliklinik für Innere Medizin II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Felicitas RatajCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Klara DormanCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Johannes LutzCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Clara H KarchesCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Constanze HeiseCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Mathias KurzayCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Benjamin M LarimerCenter for Precision Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1288-7206
Simon GrassmannCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Moritz RappCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Alessia NottebrockCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Stephan KrugerCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Nicholas TokarewCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Philipp MetzgerCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0001-8741-3139
Christine HoerthCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Mohamed-Reda BenmebarekCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-1201-7067
Dario DhoqinaCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Ruth GrünmeierCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Matthias SeifertCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-6581-6196
Arman OenerCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Öykü UmutCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Sandy JoaquinaUniversité de Paris, Institute Cochin, INSERM, CNRS, Paris, France.
Lene VimeuxUniversité de Paris, Institute Cochin, INSERM, CNRS, Paris, France.
Thi TranEquipe labellisée Ligue Contre le Cancer, Toulouse, France.
Thomas HankDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8087-2295
Taisuke BabaDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Duc HuynhCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Remco T A MegensInstitute for Cardiovascular Prevention (IPEK), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0001-9871-6696
Klaus-Peter JanssenDepartment of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-4707-7887
Martin JastrochHelmholtz Diabetes Center and German Diabetes Center (DZD), Helmholtz Zentrum München, Neuherberg, Germany.
Daniel LampHelmholtz Diabetes Center and German Diabetes Center (DZD), Helmholtz Zentrum München, Neuherberg, Germany.
Svenja RuehlandLMU Biocenter, Department Biology II, Ludwig Maximilians-Universität München, Munich, Germany.
Mauro Di PilatoCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Jasper N PruessmannCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Moritz ThomasInstitute of Computational Biology, Helmholtz Zentrum München (German Research Center for Environmental Health), Neuherberg, Germany.
Carsten MarrInstitute of Computational Biology, Helmholtz Zentrum München (German Research Center for Environmental Health), Neuherberg, Germany.
Steffen OrmannsInstitute of Pathology, Ludwig-Maximilians-Universität München, Munich, Germany.
Anna ReischerDepartment of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Michael HristovInstitute for Cardiovascular Prevention (IPEK), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Eric TartourEquipe labellisée Ligue Contre le Cancer, Toulouse, France.ORCID http://orcid.org/0000-0002-7323-468X
Emmanuel DonnadieuUniversité de Paris, Institute Cochin, INSERM, CNRS, Paris, France.
Simon RothenfusserCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-1151-7614
Peter DuewellInstitute of Innate Immunity, University of Bonn, Bonn, Germany.
Lars M KönigCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-8348-7787
Max SchnurrCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Marion SubkleweDepartment of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Andrew S LissDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4040-9172
Niels HalamaDepartment of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0344-6027
Maximilian ReichertKlinik und Poliklinik für Innere Medizin II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Thorsten R MempelCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Stefan EndresCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-4703-537X
Sebastian KoboldCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany. Sebastian.kobold@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-5612-4673
Center for Integrated Protein Science Munich · DELudwig-Maximilians-Universität München · DEGerman Cancer Research Center · DEHelmholtz Zentrum München · DEMassachusetts General Hospital · USCentre National de la Recherche Scientifique · FRHarvard University · USInserm · FRTUM Klinikum · DEMaastricht University · NLUniversity of Bonn · DE
Funding
Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI SARTOR, MAUREEN AGNES · 2019 to 2023
$8.4MCellular mechanisms by which exhausted T cell responses are restoredR01AI123349 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Thorsten Roman Mempel · 2017 to 2026
$4.5MSite-Specific Immune Cell Activation Detection for Improving Individualized Cancer ImmunotherapyDP2CA261453 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LARIMER, BENJAMIN M · 2020 to 2020
$2.2MQuantitative PET Imaging for Oncologic Immune Response PredictionR00CA215604 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LARIMER, BENJAMIN M · 2019 to 2021
$703kEuropean Research Council 756017European Research Council 866411NCI NIH HHS DP2 CA261453NCI NIH HHS P01 CA240239NCI NIH HHS R00 CA215604NIAID NIH HHS R01 AI123349
Abstract
The efficacy of adoptive cell therapy for solid tumours is hampered by the poor accumulation of the transferred T cells in tumour tissue. Here, we show that forced expression of C-X-C chemokine receptor type 6 (whose ligand is highly expressed by human and murine pancreatic cancer cells and tumour-infiltrating immune cells) in antigen-specific T cells enhanced the recognition and lysis of pancreatic cancer cells and the efficacy of adoptive cell therapy for pancreatic cancer. In mice with subcutaneous pancreatic tumours treated with T cells with either a transgenic T-cell receptor or a murine chimeric antigen receptor targeting the tumour-associated antigen epithelial cell adhesion molecule, and in mice with orthotopic pancreatic tumours or patient-derived xenografts treated with T cells expressing a chimeric antigen receptor targeting mesothelin, the T cells exhibited enhanced intratumoral accumulation, exerted sustained anti-tumoral activity and prolonged animal survival only when co-expressing C-X-C chemokine receptor type 6. Arming tumour-specific T cells with tumour-specific chemokine receptors may represent a promising strategy for the realization of adoptive cell therapy for solid tumours.
Indexed as
Immunotherapy, AdoptivePancreatic NeoplasmsT-LymphocytesAnimalsCell- and Tissue-Based TherapyMesothelinMiceReceptors, ChemokineReceptors, CXCR6Cxcr6 protein, mouseMesothelinReceptors, ChemokineReceptors, CXCR6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.